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Tolerability of Aquaretic-Related Symptoms
Following Tolvaptan for Autosomal
Dominant Polycystic Kidney Disease:
Results From TEMPO 3:4
Olivier Devuyst1,2, Arlene B. Chapman3, Susan E. Shoaf4, Frank S. Czerwiec4 and
Jaime D. Blais4
1Institute of Physiology, University of Zurich, Zurich, Switzerland; 2Division of Nephrology, Université catholique de Louvain
Medical School, Brussels, Belgium; 3Division of Nephrology, Emory University School of Medicine, Atlanta, Georgia, USA; and
4Otsuka Pharmaceutical Development & Commercialization, Rockville, Maryland, USA
Introduction: In the randomized placebo-controlled Tolvaptan Efﬁcacy and Safety in Management of
Autosomal Dominant Polycystic Kidney Disease and its Outcomes (TEMPO) 3:4 trial, tolvaptan slowed
kidney growth and renal function decline in subjects with autosomal dominant polycystic kidney disease
(ADPKD). Consistent with its primary pharmacologic activity, tolvaptan use was commonly associated
with aquaretic adverse events (AAEs) attributable to excess free water clearance.
Methods: A post hoc analysis of tolvaptan-related discontinuations from the pivotal randomized
controlled trial TEMPO 3:4 and its open-label extension TEMPO 4:4.
Results: In total, 750 of 961 tolvaptan-treated subjects (78%) in TEMPO 3:4 reported at least one AAE. Of these
750 subjects, 72 (10%) discontinued because of an AAE (aquaretic-discontinued group) and 573 (76%)
continued (aquaretic-continued group). The aquaretic-discontinued subjects were younger, had better baseline
renal function, and had higher fasting urine osmolality than aquaretic-continued subjects. Of the 750 subjects
reporting an AAE, 105 (14%) discontinued for another reason (non-aquaretic-discontinued group). Compared
to non-aquaretic-discontinued subjects, aquaretic-discontinued subjects were more commonly male, had
better baseline renal function, and discontinued the study drug faster. After 3 years of therapy, 75% of tol-
vaptan subjects indicated that they could tolerate their current dose for the rest of their lives, compared to 85%
of placebo subjects. These ﬁndings were corroborated by results in the open-label extension trial TEMPO 4:4.
Discussion: In this study, AAEs were common but well tolerated in ADPKD patients on tolvaptan. ADPKD
patients in earlier stages of disease progression may be more sensitive to aquaretic symptoms, which may
help in guiding tolvaptan dosing and titration decisions in the future.
Kidney Int Rep (2017) 2, 1132–1140; http://dx.doi.org/10.1016/j.ekir.2017.07.004
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A utosomal dominant polycystic kidney disease(ADPKD) is an inherited disorder characterized by
the appearance and slow growth of ﬂuid-ﬁlled cysts in
the kidneys, liver, and other organs.1,2 In the kidney,
the expanding cysts obstruct renal tubules, blood ves-
sels and lymphatics, resulting in apoptosis, atrophy,
and ﬁbrosis.3 As the cysts grow, the kidneys gradually
and progressively enlarge, which may ultimately cause
end-stage renal disease (ESRD); thus, approximately
50% of patients with ADPKD have ESRD by 60 years
of age.4 The disease was responsible for 2.6% of pa-
tients on dialysis and 9.9% of patients receiving renal
transplants in 2012 in the United States,5 making it the
fourth leading cause of ESRD, behind diabetes, hyperten-
sion, and glomerulonephritis.6 The prevalence of ADPKD
patients on renal replacement therapy (RRT) in the Euro-
pean Union has been estimated at 91.1 per million.7
In the past, therapy for ADPKD was symptomatic,
relying primarily on antihypertensives, analgesics,
RRT, and transplantation. Recently, however, phar-
macotherapy with tolvaptan has proved to have
beneﬁcial disease-modifying activity in patients with
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ADPKD.8,9 Tolvaptan is an oral selective antagonist of
the V2 receptor, the key binding site of the antidi-
uretic hormone arginine vasopressin (AVP), and acts
by lowering the levels of cyclic AMP within the distal
renal tubule epithelium, the major site of cyst devel-
opment in ADPKD.1,2,10 Blockade of the V2 receptor
has been shown to have an anti-proliferative effect
that slows cyst development in orthologous model
systems.11–15 In the pivotal Phase 3 trial Tolvaptan
Efﬁcacy and Safety in Management of Autosomal
Dominant Polycystic Kidney Disease and its Outcomes
(TEMPO 3:4), treatment with tolvaptan halved the
rates of total kidney volume growth relative to pla-
cebo.8,9 These effects were associated with other
favorable outcomes, including a lower rate of wors-
ening renal function and a lower rate of worsening
kidney pain.
By antagonizing the activity of AVP in renal tubule
cells, tolvaptan induces aquaresis (i.e., increased free
water clearance and decreased urine osmolality) and
increased serum sodium concentrations.16 In fact,
tolvaptan was initially approved for the treatment of
clinically signiﬁcant hyponatremia, including patients
with heart failure and syndrome of inappropriate
antidiuretic hormone. Consistent with its mechanism
of action, the use of tolvaptan in clinical trials has
been associated with aquaretic adverse events (AAEs).
Given their high frequency, AAEs might be expected
to impose some limitations on tolvaptan use in the
clinic, but this has not been directly examined. To
dissect this issue in more detail, the current sub-
analysis of the TEMPO 3:4 trial and its open-label
extension TEMPO 4:4 characterized the impact of
tolvaptan-related AAEs on a subject’s decision to
discontinue from the trial. This study also aimed to
identify characteristics of ADPKD patients who were at
increased risk for AAEs, which may allow for better
tolvaptan titration regimens and encourage compliance.
METHODS
Trial Design
This was a post hoc, exploratory subanalysis of the
TEMPO 3:4 trial (ClinicalTrials.gov identiﬁer:
NCT00428948).8,9 TEMPO 3:4 was a Phase 3, multi-
center, double-blind, placebo-controlled, 3-year trial
assessing the efﬁcacy and safety of tolvaptan in sub-
jects with ADPKD. Eligibility requirements included a
diagnosis of ADPKD according to the Ravine criteria, a
total kidney volume of $ 750 ml as measured by
magnetic resonance imaging (MRI), an estimated
creatinine clearance rate of $ 60 ml per minute as
calculated by the Cockcroft–Gault formula, and an age
of 18 to 50 years. A total of 1445 eligible subjects were
randomly assigned in a 2:1 ratio to receive either tol-
vaptan (n ¼ 961) or matching placebo (n ¼ 484).
Following randomization, subjects were to be admin-
istered 2 doses of study drug per day for 3 years,
initiating with a 3-week titration period. During the
ﬁrst week of the titration period, the active arm
received tolvaptan at a dose of 45 mg in the morning
and 15 mg in the afternoon. This split dose was
increased to 60/30 mg in the second week and to 90/30
mg in the third week according to subject-reported
tolerability. Subjects were allowed to down-titrate to
45/15 mg at any time during the trial but were advised
to remain on their highest tolerated dose throughout
the remaining trial period. The investigators were
instructed on the necessity to explain the mechanism of
action of the drug in relation to expected AAEs
including polyuria and the need to compensate with
adequate water intake.
To conﬁrm any conclusions about AAEs in TEMPO
3:4, we further examined prior placebo subjects who
crossed over to open-label tolvaptan in TEMPO 4:4
(ClinicalTrials.gov identiﬁer: NCT01214421).17 TEMPO
4:4 was a nonrandomized, open-label extension of
TEMPO 3:4 that sought to determine whether tol-
vaptan modiﬁed the progression of ADPKD and
whether its effects could be sustained over time. The
trial included 871 patients on open-label tolvaptan, 557
who had received tolvaptan in TEMPO 3:4 and 314
who had received placebo. The entry criteria were
completion of TEMPO 3:4 and an eGFRMDRD $ 30 ml/
min per 1.73 m2. Treatment used the same split-dose
regimens as the TEMPO 3:4 trial for a minimum of 2
years. Initiation of dosing used the same titration
scheme over the ﬁrst 4 weeks with down-titration to
45/15 mg or lower after discussion with the medical
monitor after the ﬁrst month.
Assessments
In both studies, AAEs were deﬁned as thirst, polyuria
(production of large volumes of dilute urine), nocturia
(need to wake up to urinate at night), pollakiuria
(abnormally frequent urination), and polydipsia
(excessive thirst). All adverse events were counted
once per subject per speciﬁc event.
Three subpopulations of tolvaptan-treated sub-
jects from TEMPO 3:4 and TEMPO 4:4 were exam-
ined in the current study: those who reported an
AAE and continued on study drug; those who re-
ported an AAE but discontinued for another AE; and
those who reported an AAE that led to trial discon-
tinuation. These are referred to in this report
as aquaretic-continued (AC), non–aquaretic-dis-
continued (NAD), and aquaretic-discontinued (AD),
respectively. Subjects who experienced an AAE were
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analyzed separately for those who continued or dis-
continued the trial and separately for those who
discontinued the trial due to polyuria versus all other
combined aquaretic AAEs.
Speciﬁc assessments conducted on the individual
subpopulations included the following: frequency and
timing of AAEs and non-AAEs leading to trial
discontinuation; dose of tolvaptan at trial discontinu-
ation; highest titrated dose of tolvaptan before
discontinuation; baseline demographics, including age,
sex, height-adjusted total kidney volume (htTKV),
renal function (eGFRCKD-EPI), and fasting baseline urine
osmolality (uOsm).
In addition, in a patient-reported outcome analysis
in TEMPO 3:4, the percentage of subjects who tolerated
their current dose of study drug was determined. The
analysis was based on a questionnaire that asked,
among other queries, whether the subject could
tolerate his or her current dose of study drug for the
rest of his or her life (those who answered “no” to this
question were either titrated to a lower dose of medi-
cation or discontinued from the trial).
Statistical Analyses
Baseline characteristics were calculated for subjects
who reported an AAE separately for those who
continued or discontinued the trial and separately for
those who discontinued the trial due to polyuria versus
all other combined aquaretic AAEs. Moreover, those
who discontinued the trial for a reason other than an
AAE were further assessed by reason for discontinua-
tion: (i) due to an AE other than an AAE (n ¼ 57) or (ii)
for another reason (n ¼ 48), which included lost to
follow-up (n ¼ 11), subject met withdrawal criteria
(n ¼ 3), investigator withdrew subject (n ¼ 2) and
subject withdrew consent (n ¼ 32). This analysis re-
ports the full population of individuals who dis-
continued for reasons other than an AAE (n ¼ 105) and
the subpopulation who discontinued because of
another AE (n ¼ 57) in Table 1.
Parametric variables were expressed as mean  SD.
Differences in baseline characteristics were calculated
with a Fisher exact test for categorical data and a
Mann–Whitney–Wilcoxon test for continuous data.
Time to ﬁrst report of an AAE and time to discon-
tinuation are presented as median (interquartile range
[IQR]). Difference in time between subjects who re-
ported an AAE and continued or discontinued the
trial was calculated with a Mann–Whitney–Wilcoxon
test. Time to discontinuation of the trial is expressed
as median (IQR). Difference in time between subjects
who discontinued the trial due to an AAE or other
reason was calculated with a Mann–Whitney–Wil-
coxon test. Differences in the proportions of patients
maintaining the target dose according to the report of
an AAE or not were assessed with a Fisher exact test.
Table 1. Subpopulation characteristics in TEMPO 3:4
Subgroup n Age, mean (SD), yr Male, %
Baseline eGFR,
mean (SD),
ml/min per 1.73 m2
Baseline
htTKV, mean
(SD), ml/m
Baseline fasting
uOsm. mean (SD),
mOsm/kg
Time to ﬁrst
AAE report,
median (IQR), day
Time to discontinuation,
median (IQR), day
All tolvaptan-treated subjects 961 38.6 (7.1) 52 81.3 (21.0)
n ¼ 958
979 (515) 500 (173)
n ¼ 700
Tolvaptan subjects without AAE 211 38.4 (6.7) 46 80.6 (20.6) 1033 (563) 511.7 (170)
n ¼ 147
Tolvaptan subjects with AAE 750 38.6 (7.2) 53 81.6 (21.1)
n ¼ 747
963 (500) 496 (173)
n ¼ 553
Continued (AC) 573 38.9 (7.1)a 53 80.9 (20.9)f
n ¼ 675
957 (478) 492 (176)k
n ¼ 504
2 (1–8)
Discontinued AAE (AD) 72 36.2 (7.8)a,b 57c,d 88.2 (22.2)e,f,g
n ¼ 72
915 (521)i,j 544 (134)k
n ¼ 49
2 (1–6) 96 (15–209)l,m
Polyuria 40 36.4 (8.6) 50 95.6 (18.6)h 843 (385) 555 (126)
n ¼ 27
All other AAEs 32 36.0 (7.0) 66 79.0 (23.0)h 1005 (648) 531 (146)
n ¼ 22
Discontinued other (NAD) 105 38.3 (7.5) 41d 78.7 (21.6)g 1032 (595)i 490 (158)
n ¼ 76
1 (1–6) 372 (121–631)m
All other AEs 57 40.0 (7.1)b 35c 73.6 (19.2)e 1046 (518)j 486 (164)
n ¼ 42
1 (1–4) 288 (121–577)l
AAE, aquaretic adverse event, AC, aquaretic-continued; AD, aquaretic-discontinued; eGFR, estimated glomerular ﬁltration rate, calculated by Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation; htTKV, height-adjusted total kidney volume; IQR, interquartile range; NAD, non–aquaretic-discontinued; TEMPO, Tolvaptan Efﬁcacy and Safety in
Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes; uOsm, urine osmolality.
aP ¼ 0.006; bP ¼ 0.007; cP ¼ 0.02; dP < 0.05; eP ¼ 0.006; fP ¼ 0.0001; gP ¼ 0.005; hP ¼ 0.001; iP ¼ 0.04; jP ¼ 0.03; kP < 0.05; lP < 0.0001; mP < 0.0001.
Data are presented on subjects allocated to tolvaptan treatment.
Subjects who discontinued for reasons other than AAEs include other AE (n ¼ 57, 54%), lost to follow-up (n ¼ 11, 11%), subject met withdrawal criteria (n ¼ 3, 3%), investigator withdrew
subject (n ¼ 2, 2%), subject withdrew consent (n ¼ 32, 31%).
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All analyses were performed with SAS 9.2 (SAS
Institute, Cary, NC) statistical software, and a 2-sided
value of P < 0.05 was considered to indicate statistical
signiﬁcance.
RESULTS
Characteristics of Tolvaptan-Treated Subjects
Who Reported an AAE
In TEMPO 3:4, 750 of 961 tolvaptan-treated subjects
(78%) reported at least 1 AAE (AAE population),
whereas 211 (22%) reported no such event (non-AAE
population) (Figure 1A). Of the 750 reporting an AAE,
177 (24%) subjects discontinued, including 72 (10%)
due to the aquaretic event (aquaretic-discontinued
[AD]) and 105 (14%) for another reason (non–aquaretic-
discontinued [NAD]). Treatment was not discontinued
in 573 (76%) reporting an AAE (aquaretic-continued
[AC]).
No signiﬁcant differences were observed between
the AAE and non-AAE populations, but differences
were detected within the AAE population itself
(Table 1). For example, AD subjects were signiﬁcantly
younger (36.2  7.8 vs. 38.9  7.1 years; P ¼ 0.006),
had higher baseline renal function (eGFRCKD-EPI, 88.2
 22.2 vs. 80.9  20.9 ml/min per 1.73 m2; P ¼
0.006), and higher fasting baseline uOsm (544  134
vs. 492  176 mOsm/kg; P ¼ 0.045) than AC subjects
(Figure 2). Similarly, when compared with NAD
subjects, AD subjects were more likely to be male (57
vs. 41%, P < 0.05), had higher baseline renal func-
tion (88.2  22.2 vs. 78.7  21.6 ml/min per 1.73 m2;
P ¼ 0.005), had lower baseline htTKV (915  521 vs.
1032  595 ml/m, P ¼ 0.03), and were faster to dis-
continue the trial (median [IQR], 96 [15–209] vs. 372
[121–631] days; P < 0.0001). AD subjects were
younger (36.2  7.8 vs. 40.0  7.1 years, respectively,
P ¼ 0.007) than subjects in the NAD group who
discontinued for a different AE (N ¼ 57).
In the AD subgroup, the most common AAE
leading to discontinuation was polyuria, accounting
for 56% (n ¼ 40) of the total, followed by pollakiuria
(15 [21%]), nocturia (9 [13%]), thirst (6 [8%]), and
polydipsia (2 [3%]), respectively (Figure 3). Thus,
trial discontinuation was caused by polyuria more
frequently than all other AAEs combined. Subjects
who discontinued because of polyuria had signiﬁ-
cantly higher baseline renal function than subjects
who discontinued for other AAEs (eGFRCKD-EPI,
95.6  18.6 vs. 79.0  23.0 ml/min per 1.73 m2;
P ¼ 0.001).
Figure 1. Flow chart of tolvaptan subjects into categories of par-
ticipants who reported or did not report an aquaretic adverse event
(AAE). (a) Tolvaptan subjects in the Tolvaptan Efﬁcacy and Safety
in Management of Autosomal Dominant Polycystic Kidney Disease
and its Outcomes (TEMPO) 3:4 trial. (b) Prior placebo subjects in
TEMPO 4:4. AC, aquaretic-continued; AD, aquaretic-discontinued;
AE, adverse event; NAD, non–aquaretic discontinued.
Figure 2. Urine osmolality in tolvaptan subjects who reported an
aquaretic adverse event (AAE). All patient data points are plotted as
circles. Box plot shows mean and interquartile range of fasting
baseline urine osmolality. AC, aquaretic-continued; AD, aquaretic-
discontinued; AE, adverse event; Discont., discontinued; max,
maximum; min, minimum; NAD, non–aquaretic-discontinued.
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To validate these ﬁndings, the cohort of subjects
who crossed over from placebo in TEMPO 3:4 to tol-
vaptan in the open-label extension trial TEMPO 4:4
were also examined (Figure 1B). In total, 234 of 314
(75%) prior placebo subjects reported an AAE
following the switch to tolvaptan. Similar to the tol-
vaptan group in TEMPO 3:4, 21 of 234 subjects (9%)
discontinued due to an AAE (Table 2). The AD subjects
had signiﬁcantly higher baseline renal function than
the AC subjects (72.4  30.5 vs. 67.5  23.1 ml/min per
1.73 m2; P ¼ 0.048). The AD subjects also discontinued
the trial faster than the NAD subjects (median [IQR],
196 [49–910] vs. 658 [216–1218] days, P ¼ 0.02).
Aswas the case in TEMPO 3:4, AD subjects in TEMPO
4:4 were more likely to discontinue because of polyuria
than all other AAEs combined (n ¼ 17 vs. n ¼ 4).
Subjects who discontinued because of polyuria had
lower baseline htTKV and higher baseline renal func-
tion than those who discontinued because of other
AAEs (Table 2).
Aquaretic Adverse Events in Tolvaptan-Treated
Subjects in TEMPO 3:4: Dose, Timing, and Urine
Osmolality Relationships
Among the 72 patients comprising the AD population
of TEMPO 3:4, 22 (31%), 16 (22%), and 34 (47%) had
titrated to a maximum split-daily dosage of 45/15 mg,
60/30 mg, and 90/30 mg, respectively. Analogous
numbers for TEMPO 4:4 were 13 (62%), 2 (10%), and 6
(28%), respectively (Figure 4). Down-titration of tol-
vaptan was permitted in both trials at any time based
on tolerability. Before discontinuation, nearly all sub-
jects in the AD populations of both trials had down-
titrated to 45/15 mg or had stopped taking study
drug before formally withdrawing from the trial.
Both AD and AC subjects in TEMPO 3:4 reported
AAEs relatively soon after entering the treatment
phase, that is, a median of 2 days after the ﬁrst dose of
tolvaptan in both subgroups (Table 1). The median
(IQR) time to discontinuation for AD subjects was 96
(15–209) days, which was signiﬁcantly shorter than
the 372 (121–631) days observed among NAD subjects
(P < 0.0001) (Figure 5).
Tolerance of Tolvaptan Relative to Placebo in
TEMPO 3:4
At each visit, subjects were asked if they could tolerate
their current dose of medication for the rest of their
life. A relatively rapid increase in the percentage of
subjects answering “no” to this question occurred
during the initial titration period (Figure 6), which
resulted in down titration or trial discontinuation. The
majority of early discontinuations by week 3 were due
to AAEs (30/47 [64%]) (Table 3). The tolerability of
tolvaptan appeared to stabilize by the month 4 visit. At
the end of the trial (3 years), 75.4% of subjects who
were still receiving tolvaptan indicated that they could
tolerate their current dose of medication for the rest of
their lives, compared with 85.5% of placebo patients.
Analysis of the dose regimen at the end of TEMPO 3:4
and 4:4 (Table 4) showed that patients who did not
report an AAE were better able to maintain the target
dose of 90/30mg than those who reported an AAE in
both trials (TEMPO 3:4: 130 of 167 vs. 271 of 573,
P < 0.0001; TEMPO 4:4: 46 of 74 vs. 77 of 182,
P ¼ 0.0056, respectively).
DISCUSSION
The most common side effects associated with tol-
vaptan use in TEMPO 3:4 were related to aquaresis.
Thirst (55.3% of tolvaptan-treated subjects vs. 20.5%
of placebo-treated subjects; P < 0.001), polyuria
(38.3% vs. 17.2%; P < 0.001), and nocturia (29.1% vs.
13.0%; P < 0.001) were the most commonly reported
adverse events, whereas pollakiuria (23.2% vs. 5.4%;
P < 0.001) and polydipsia (10.4% vs. 3.5%; P < 0.001)
were the ﬁfth and tenth most commonly reported
adverse events, respectively. These occurred soon after
study drug initiation (median, 2 days) and were ranked
on subject self-reports as most intolerable during the
Figure 3. Frequency of aquaretic adverse events that led to trial
discontinuation of tolvaptan subjects in the Tolvaptan Efﬁcacy and
Safety in Management of Autosomal Dominant Polycystic Kidney
Disease and its Outcomes (TEMPO) 3:4 trial. Nocturia, need to wake
up to urinate at night; pollakiuria, abnormally frequent urination;
polydipsia, excessive thirst; polyuria, production of large volumes of
dilute urine.
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initial 3-week titration period. Once adjusted to the
aquaretic side effects, overall tolerability to ongoing
therapy was very favorable in the ADPKD trial popu-
lation. In fact, 75% of subjects who were still receiving
tolvaptan at 3 years indicated that they could tolerate
their current dose of medication for the rest of their
lives, compared with 85% of placebo patients.
Accordingly, only 10% of subjects withdrew because
of an AAE over the course of the trial. The tolvaptan-
treated subjects who did withdraw because of an AAE
were signiﬁcantly younger, had better baseline renal
function, and had higher fasting baseline urine osmo-
lality values than subjects with AAEs who remained in
the trial or subjects who discontinued for a non–
aquaretic-related AE. These results are consistent with
the recent observation that the initial aquaretic
response to tolvaptan correlates positively with base-
line urine osmolality and baseline eGFR.16 In other
words, patients with less advanced disease are more
responsive to the pharmacologic action of tolvaptan,
and thus experience more pronounced aquaresis.16
Aquaretic-related discontinuations in tolvaptan-
naive subjects from TEMPO 3:4 who crossed over to
tolvaptan treatment in the open-label extension trial
TEMPO 4:4 were largely consistent with the ﬁndings
from TEMPO 3:4, despite the smaller cohort of subjects
(n ¼ 961 vs. n ¼ 314, tolvaptan [TEMPO 3:4] vs. prior
placebo [TEMPO 4:4]). In general, the safety proﬁle for
tolvaptan in TEMPO 4:4 was similar to that in TEMPO
3:4. Most adverse events were related to the aquaretic
effect of tolvaptan. These AAEs were more frequently
reported in the delayed-treatment group who had not
been previously exposed to tolvaptan. The higher
proportion of subjects in TEMPO 4:4 who did not
titrate past the starting dose of 45/15 mg could be
attributed to a more relaxed outlook on pushing titra-
tion to the maximum tolerated dose, as this was an
open-label extension and not a pivotal Phase 3 clinical
trial.17
Although most tolvaptan-naive subjects from
TEMPO 3:4 and TEMPO 4:4 attempted to down-titrate
before discontinuation, a large cohort of subjects never
titrated past the starting dose of 45/15 mg (TEMPO 3:4,
n ¼ 22 [31%]; TEMPO 4:4, n ¼ 13 [62%]). This might
indicate that they experienced a higher amount of
aquaresis than other subjects. In earlier studies on the
short-term effects of tolvaptan, higher 24-hour urine
volume excretion was experienced by subjects with
higher baseline renal function.18–20 As discussed above,
higher response to tolvaptan in TEMPO3:4 was also
observed in patients with better preserved renal
function.16 In addition, subjects in earlier stages of
disease may be more sensitive to the increase in urine
output. Given that urine concentrating ability de-
creases with disease progression, subjects in later stages
of disease may be more accustomed to managing a
higher urine volume and, consequently, may perceive
the polyuria and nocturia associated with increased
aquaresis as being less burdensome.18–20
From a mechanistic perspective, elevated cAMP
levels in renal tubule epithelial cells play a key
role in ADPKD pathogenesis.21 Achieving maximal
Table 2. Subpopulation characteristics in TEMPO 4:4
Subgroup n Age, mean (SD), yr Male, %
Baseline eGFR,
mean (SD),
ml/min per 1.73 m2
Baseline htTKV,
mean (SD), ml/m
Baseline dasting
uOsm, mean (SD),
mOsm/kg
Time to ﬁrst AAE
report, median
(IQR), d
Time to discontinuation,
median (IQR), d
All prior placebo subjects 314 42.5 (7.2) 50 66.6 (25.4)
n ¼ 253
1196 (676)
n ¼ 289
442 (165)
n ¼ 309
Prior placebo without AAE 80 42.1 (8.0) 58 62.4 (24.4)
n ¼ 74
1286 (773)
n ¼ 72
429 (149)
n ¼ 77
Prior placebo with AAE 234 42.6 (6.9) 48 68.4 (25.6)
n ¼ 179
1167 (640)
n ¼ 217
446 (171)
n ¼ 232
Continued (AC) 182 43.3 (6.5) 47 67.5 (23.1)a
n ¼ 135
1153 (615)c
n ¼ 170
440 (169)
n ¼ 180
1 (1–2)
Discontinued (AD) 21 41.2 (8.1) 62 72.4 (30.5)a,b
n ¼ 18
1145 (604)c
n ¼ 18
445 (152) 1 (1–2) 196d (49–910)
Polyuria 17 41.2 (7.8) 59 78.8 (27.2)
n ¼ 15
981 (474)
n ¼ 14
443 (148)
All other AAEs 4 41.0 (10.5) 75 40.4 (29.5)
n ¼ 3
1719 (729)
n ¼ 4
453 (191)
Discontinued Other AE (NAD) 31 44.3 (4.5) 48 51.9 (29.3)b
n ¼ 25
1499 (910)
n ¼ 27
425 (132) 1 (1–2) 658d (216–1218)
AAE, aquaretic adverse event, AC, aquaretic-continued; AD, aquaretic-discontinued; eGFR, estimated glomerular ﬁltration rate, calculated by Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation; htTKV, height-adjusted total kidney volume; IQR, interquartile range; NAD, non–aquaretic-discontinued; TEMPO, Tolvaptan Efﬁcacy and Safety in
Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes; uOsm, urine osmolality.
aP ¼ 0.003; bP ¼ 0.048; cP ¼ 0.02; dP ¼ 0.02.
Data are presented on subjects who were on placebo in TEMPO 3:4 and switched to tolvaptan in TEMPO 4:4.
Subjects who discontinued for other reasons include the following: other AE (n ¼ 17, 55%), completed (n ¼ 11, 36%), investigator withdrew (n ¼ 1, 3%), subject withdrew
consent (n ¼ 2, 6%).
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antagonism of cAMP via V2-receptor inhibition, that is,
titrating tolvaptan to its highest available dose, is thus
expected to have maximal clinical beneﬁt. This thera-
peutic goal, however, must be balanced by the recog-
nition that excessive aquaresis can be an important
factor limiting compliance; thus, 750 of 961 tolvaptan-
treated subjects in TEMPO 3:4 (78%) reported at least 1
AAE, of whom 72 (10%) discontinued from the trial
because of an aquaretic-related event. The current
subanalysis identiﬁed 2 important risk factors for tol-
vaptan discontinuation in ADPKD patients. First, sub-
jects with better renal function, as measured by higher
eGFR, and subjects with a greater ability to concentrate
their urine were more likely to discontinue tolvaptan.
Second, sensitivity to tolvaptan-mediated AAEs
appeared most pronounced early after drug initiation,
as observed by the signiﬁcant difference in time to
discontinuation between AD and NAD groups (96 vs.
372 days, P < 0.0001, respectively) and those who
discontinued for other AEs (96 vs. 288 days,
P < 0.0001). This ﬁnding is supported by the early-
treatment group in TEMPO 4:4, who had completed 3
years of tolvaptan treatment in TEMPO 3:4. Although
Figure 5. Time to discontinuation due to aquaretic and non-
aquaretic adverse events. Box plot of median and interquartile range
of time to discontinuation in the aquaretic-discontinued (AD) and
non–aquaretic-discontinued (NAD) groups. Data points above and
below the 75th and 25th quartiles are depicted in black circles. The
overall ranges were 2 to 877 days in the AD group and 8 to 1050 days
in the NAD group. Discont., discontinued; max, maximum; min, mini-
mum; TEMPO 3:4, Tolvaptan Efﬁcacy and Safety in Management of
Autosomal Dominant Polycystic Kidney Disease and its Outcomes.
Figure 6. Percentage of subjects tolerating their current dose of
study drug during the Tolvaptan Efﬁcacy and Safety in Management
of Autosomal Dominant Polycystic Kidney Disease and its Outcomes
(TEMPO) 3:4 trial. 3w, 3 weeks (refers to the time point taken at the
end of the titration period).
Figure 4. Dose of tolvaptan at discontinuation relative to the highest
titrated dose in aquaretic-discontinued (AD) subjects. Subjects were
titrated to the highest tolerated dose of 45/15, 60/30, or 90/30 mg/d
and were permitted to down-titrate as needed during the trial. The
highest titrated dose is plotted on the x-axis, and the dose at the
time of discontinuation (90/30, 60/30, 45/15, < 45/15 mg/d) is plotted
as a box plot based on percentage of patients. (a) Tolvaptan Efﬁcacy
and Safety in Management of Autosomal Dominant Polycystic Kid-
ney Disease and its Outcomes (TEMPO) 3:4. (b) TEMPO 4:4.
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they continued to report a high frequency of AAEs
(350 of 557 [63%]), very few discontinued because of
an AAE (3 of 350 [1%]). This was further validated in
the recent Replicating Evidence of Preserved Renal
Function: An Investigation of Tolvaptan Safety and
Efﬁcacy in ADPKD (REPRISE) trial, which used a tol-
vaptan titration (2 weeks) and run-in period (3 weeks)
to enrich the trial for subjects who could tolerate tol-
vaptan treatment, to minimize the number of early
aquaretic-related discontinuations.22 Of the 1491 sub-
jects who entered the tolvaptan titration period,
adverse events led to the discontinuation of treatment
in 6.8% of subjects, most of them (4.6%) aquaretic-
related, consistent with the ﬁndings in this report.
Practically, this argues that clinicians should take
particular care when administering tolvaptan to
ADPKD patients who are in early stages of their dis-
ease, in particular starting at a low dose (45/15 mg) and
delaying subsequent titration until tolerability has
been established.
Given that enrollment in the open-label extension
trial TEMPO 4:4 occurred continuously upon
completion of TEMPO 3:4, the vast majority of sub-
jects were unaware of the positive efﬁcacy data from
the pivotal TEMPO 3:4 trial, as the data were not
unblinded or published. Indeed, 9% of prior placebo
subjects discontinued the TEMPO 4:4 trial because of
AAEs associated with tolvaptan treatment, similar to
the 10% AAE discontinuations reported in TEMPO
3:4. An intriguing issue is whether tolerability in real
life could be higher than in the setting of the trial.
Clinical experience suggests that patients newly
exposed to tolvaptan may be more tolerant to poly-
uria, as many were already exposed to high water
intake. More generally, patients may be more inclined
to accept adverse events resulting from the mode of
action of a given drug, once that drug has been
approved. The fact that post hoc analyses from the
TEMPO 4:4 trial showed positive outcomes for the
subgroup of rapid progressors, that is, those patients
eligible for tolvaptan prescription, may also be a
motivating factor.17
The aim of dose titration is to block activity of
vasopressin at the renal V2 receptor as completely and
constantly as possible, while maintaining acceptable
ﬂuid balance. The adequacy of vasopressin suppres-
sion can be monitored through measurement of fast-
ing trough urine osmolality, which could prove to be
an effective strategy to optimize dose titration and
tolerability to treatment.16 In a recent post hoc anal-
ysis of TEMPO 3:4, subjects with the greatest mean
change from baseline in urine osmolality were
more likely to achieve a better clinical response as
measured by slowed renal function decline.16 A target
decrease of $300 mOsm/kg from baseline may be
considered ideal in most cases, although a decrease
of $200 mOsm/kg from baseline may be appropriate
in patients who are relatively early in their disease
course and are likely to be more sensitive to the
aquaretic side effects of tolvaptan. If possible, an
absolute urine osmolality <300 mOsm/kg should be
maintained at all times. Thus, measuring changes in
urine osmolality over time could help guide dosing
and titration decisions.
In conclusion, to support long-term compliance,
tolvaptan dosing and titration decisions in ADPKD
patients with high baseline renal function and high
fasting baseline urine osmolality should be approached
conservatively and in partnership with the patient
before initiating therapy.
Table 3. Reasons for early discontinuation during dose titration
period (up to week 3) in TEMPO 3:4
Reason for discontinuation (n [ 47) n (%)
Reported an AAE 41 (87)
Discontinued (AD) 30 (64)
Discontinued for other reason (NAD) 11 (23)
Discontinued without reporting AAE 1 (2)
Subject withdrew consent 4 (9)
Protocol deviation 1 (2)
AAE, aquaretic adverse event; AD, aquaretic-discontinued; NAD, non–aquaretic-dis-
continued; TEMPO, Tolvaptan Efﬁcacy and Safety in Management of Autosomal
Dominant Polycystic Kidney Disease and its Outcomes.
Table 4. Proportion of patients on various treatment regimens at the
end of the TEMPO 3:4 and 4:4 trials: Inﬂuence of aquaretic adverse
events
TEMPO 3:4 n (%)
No AAE 167 (100)
45/15 mg 19 (11)
60/30 mg 18 (11)
90/30 mg 130 (78)
AC 573 (100)
45/15 mg 157 (27)
60/30 mg 145 (25)
90/30 mg 271 (47)
TEMPO 4:4 n (%)
No AAE 74 (100)
45/15 mg 16 (22)
60/30 mg 12 (16)
90/30 mg 46 (62)
AC 182 (100)
45/15 mg 71 (39)
60/30 mg 34 (19)
90/30 mg 77 (42)
AAE, aquaretic adverse event; AC, aquaretic adverse event continued; No AAE, no
aquaretic adverse event; TEMPO, Tolvaptan Efﬁcacy and Safety in Management of
Autosomal Dominant Polycystic Kidney Disease and its Outcomes.
Proportion of patients maintaining the target dose of 90/30 mg, No AAE versus AC:
TEMPO 3:4, 130 of 167 versus 271 of 573, P < 0.0001; TEMPO 4:4, 46 of 74 versus 77 of
182, P ¼ 0.0056, respectively).
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